Rigel Pharmaceuticals : January 2023

Corporate Presentation

J a n u a r y 2 0 2 3

1

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, expected commercial and financial results for the fourth quarter and fiscal year ended December 31, 2022; Rigel's ability to earn and receive milestone payments; expectations related to the potential and market opportunity of olutasidenib as therapeutics for R/R AML and other conditions; expectations related to Japan's PMDA approval of TAVALISSE for the treatment of chronic ITP; the progress of Phase 1b clinical trial of R289 for the treatment of lower-risk myeloid dysplastic syndrome; the advancement of Phase 2a clinical trial of R552 for the treatment of rheumatoid arthritis; the results of Phase 1 clinical trial of fostamatinib for the treatment of chronic graft-versus-host disease; the capabilities of Rigel's existing commercial infrastructure; the commercial success and ability to grow sales of TAVALISSE in the U.S. and TAVLESSE in Europe, including expectations related to the potential and market opportunity for fostamatinib as therapeutic for, among other things, COVID-19; the regulatory approval and commercialization of fostamatinib in international markets; Rigel's ability to further develop its clinical stage and early-stage product candidates and programs including its IRAK1/4 inhibitor program; and Rigel's partnering efforts and ability to achieve regulatory and commercial milestones and earn and receive milestone payments.

Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. Words such as "potential", "may", "expects", and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel's current expectations and information available to Rigel on the date of this presentation. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of TAVALISSE, TAVLESSE and REZLIDHIA; risks that the FDA, European Medicines Agency or other regulatory authorities may make adverse decisions regarding fostamatinib or olutasidenib; risks that our clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; the availability of resources to develop, manufacture and commercialize our product candidates; market competition; and those other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and subsequent filings. Rigel does not undertake any obligation to update forward- looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

2 Please visit www.TAVALISSE.com for Important Safety Information and full prescribing information. Please visit www.REZLIDHIA.com for Full prescribing information, including Boxed WARNING

Growing our Heme-Onc Business

FDA Approval and Commercial Launch of REZLIDHIATM (Olutasidenib) in R/R AML

Expanded our hematology-oncology portfolio with REZLIDHIA, now approved for the treatment adult patients with relapsed or refractory acute myeloid leukemia (AML) a potential market-leading mIDH1 inhibitor

REZLIDHIA is now available in the U.S. by prescription and the commercial launch is underway

REZLIDHIA is highly synergistic with Rigel's existing infrastructure

Grow TAVALISSE Sales in ITP

Total bottles shipped to patients and clinics in the fourth quarter of 2022 was the highest since launch1

Broad commercial coverage with preferred access status on top 3 PBMs

Continued global expansion; partner, Kissei received Japan's PMDA approval in chronic ITP, triggering a $20M milestone payment expected in the first quarter of 2023

Advance R289 in LR-MDS

R2892 IRAK1/4 inhibitor

First patients have been dosed in the open-label, Phase 1b clinical trial of R289 in patients with lower-risk MDS

Opportunistic Programs

Fostamatinib in COVID-193

Enrolling ACTIV-4 Phase 3 Study with partner NIH

RIPK1 Program in Immune and CNS diseases

Initial Phase 2a study in rheumatoid arthritis anticipated to begin in the 1H 2023 with partner, Eli Lilly

	1This information is preliminary, has not been audited and is subject to change upon completion of the audit of the company's financial statements as of and for the year ended December 31, 2022.
3	2R289 is an investigational compound not approved by the FDA. 3Investigational compound in COVID-19 indication and has not been submitted for FDA review. Please see Important Safety Information on slides 36 to 39.
	Please visit www.TAVALISSE.com for full prescribing information. Please visit www.REZLIDHIA.com for full prescribing information, including Boxed WARNING

E	ial
Hem/Onc Portfolio with
REZLIDHIA

APPROVED AND AVAILABLE IN THE U.S.

REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

Please see Important Safety Information on Slides 36 and 37 including Boxed WARNING regarding differentiation syndrome